← Leaderboards
Magdalena Leszczyniecka
Stc Biologics, Inc
$3,106,869
Attributed
$3,106,869
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.5M · FY2010–16$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,106,869 · 4
By mechanism
N44$2,499,488 · 1
R43$300,000 · 1
N43$299,881 · 1
N02$7,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Cost”
- Eric S Lander · Whitehead Institute For Biomedical Res$748,368,930
- Richard K. Wilson · Washington University$429,230,873
- Richard A Gibbs · Baylor College Of Medicine$414,258,216
- David R. Weir · University Of Michigan At Ann Arbor$393,741,481
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
Research focus
CostRecombinant ProteinsErbb2 GenePharmaceutical PreparationsGovernmentProteinsProgramsOverexpressionMonoclonal AntibodiesFeedbackGeneric DrugsHealthcareIn VivoMalignant Breast NeoplasmEngineeringBinding (Molecular Function)DesignClinical TrialsAnimalsBiochemicalDrug DevelopmentBiologicalContractsBase
Grant awards (4)
IGF::OT::IGFSTC BIOLOGICS, INC.:1183217 [15-011968]$7,500
N02 · FY2016 · DA · contact PI
A Multi-Targeting Ligand Trap to Overcome resistance in BRAF Mutant Colorectal Cancer$300,000
R43 · FY2015 · CA · contact PI
OTHER FUNCTIONS SBIR PHASE II TOPIC 275, "DEVELOPMENT OF GENERIC TRASTUZUMAB FOR$2,499,488
N44 · FY2012 · CA · contact PI
TAS::75 0849::TAS THE GOAL OF THIS PROJECT IS TO DEVELOP STC TRASTUZUMAB, A GEN$299,881
N43 · FY2010 · CA · contact PI